Skip to main navigation

Search

About
Technology Platform
- 3D Bioprinting
- Publications
News & Events
- Press Releases
- Media Coverage
Investors
Contact

Search for:

Press Releases

About
Technology Platform
- 3D Bioprinting
- Publications
News & Events
- Press Releases
- Media Coverage
Investors
Contact

Press Releases

Keyword Search

Year

Nov 20, 2024

Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting

Nov 13, 2024

Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases

Jul 16, 2024

Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis

May 21, 2024

Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease

May 14, 2024

Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)

May 08, 2024

Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering

Apr 15, 2024

Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo

Jan 25, 2024

Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress

Jan 09, 2024

Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress

Print Page RSS Feeds Investor Contacts

© 2024 Organovo Holdings, Inc. 11555 Sorrento Valley Road, Suite 100 San Diego, CA 92121

Privacy Policy

About
Technology Platform
- 3D Bioprinting
- Publications
News & Events
- Press Releases
- Media Coverage
Investors
Contact